Clinical Trials Logo

Asthma, Bronchial clinical trials

View clinical trials related to Asthma, Bronchial.

Filter by:

NCT ID: NCT00189787 Completed - Bronchial Asthma Clinical Trials

Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

NCT ID: NCT00189722 Completed - Bronchial Asthma Clinical Trials

Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.

NCT ID: NCT00092885 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effect of an approved medication on the symptoms of seasonal allergic rhinitis (a seasonal variety of inflammation of the mucous membrane of the nose) in patients who are experiencing symptoms of seasonal allergic rhinitis and asthma.

NCT ID: NCT00092105 Completed - Clinical trials for Rhinitis, Allergic, Perennial

Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)

Start date: April 1, 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.

NCT ID: NCT00092092 Completed - Asthma, Bronchial Clinical Trials

Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)

Start date: October 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the effect of montelukast, an approved medication, on the lower leg growth rate in children with mild asthma. The primary hypothesis is that the lower leg length (LLL) growth rate for children treated with montelukast compared to placebo will be established.